nootropic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
=== Gulf War === Hitchens deplored and opposed the 1990–91 Gulf War in which the US expelled Iraq from Kuwait after a seven-month invasion and occupation of its neighbor undertaken in an effort to absorb it as its 19th province. He contended that President George H. W. Bush's supposedly principled enthusiasm for the "cause" of "liberating" Kuwait was nothing more than realpolitik. In the continuation of a national policy dating back to Henry Kissinger and Richard Nixon in 1972, the latest "cause was yet another move in the policy of keeping a region divided and embittered, and therefore accessible to the franchisers of weaponry and the owners of black gold". However, after the war, Hitchens scolded those within the US who had opposed the war by observing that "the peace movement in this country in my opinion acted in a very narrow, isolationist, and almost chauvinistic way. It said that a war was more or less alright with it as long as it could be guaranteed in advance that American casualties could be kept low... I thought that was a dishonourably narrow way of approaching the question. ... When large numbers of Iraqis were turned into soap...and many others, as we've since found out, were bulldozed and buried alive and in other ways done away with and people don't even want to think about the body count ...because they're afraid of what they might find out."
A 2018 literature review of 740 records of surgeries that included recurrence rates found that primary midline closure surgeries resulted in a 67.9% recurrence rate within 20 years, and recommended that they should be discontinued due to the high recurrence rate. Incision and drainage had a recurrence rate of 25.9% within 2 years, up to 40.2% in 5 years. Phenol treatment has a recurrence rate of 14.1% at 2 years and 40.4% at 5 years. A 2024 study involving 667 people found that, compared with tissue-removing surgery, minor procedures (such as draining and pit-picking) were associated with less pain, fewer complications and a faster recovery. However, minor surgeries were less likely to resolve the condition. Surgeons can also excise the sinus and repair it with a reconstructive flap technique, such as a "cleft lift" procedure or Z-plasty, usually done under general anesthetic. This approach is especially useful for complicated or recurring pilonidal disease, leaves little scar tissue, and flattens the region between the buttocks, reducing the risk of recurrence. This approach typically results in a more rapid recovery than traditional surgery; however, there are fewer surgeons trained in the cleft lift procedure, and it consequently may not be as accessible to patients, depending on their location. Meta-analysis shows recurrence rates were lower in open healing than with primary closure (RR 0.60, 95% CI 0.42 to 0.87), at the expense of healing time.
Natural food freezing (using winter frosts) had been in use by people in cold climates for centuries. In 1861 Thomas Sutcliffe Mort established at Darling Harbour in Sydney, Australia, the world's first freezing works, which later became the New South Wales Fresh Food and Ice Company. Mort financed experiments by Eugene Dominic Nicolle, a French born engineer who had arrived in Sydney in 1853 and registered his first ice-making patent in 1861. The first trial shipment of frozen meat to London was in 1868. Although their machinery was never used in the frozen meat trade, Mort and Nicolle developed commercially viable systems for domestic trade. The financial return on that investment was minimal for Mort. Regular shipments of frozen meat from Australia and New Zealand to Europe began in 1881, with a consignment of frozen New Zealand sheep exported to London on board the Dunedin. By 1885 a small number of chickens and geese were being shipped from Russia to London in insulated cases using this technique. By March 1899, the "British Refrigeration and Allied Interests" reported that a food importing business, "Baerselman Bros", was shipping some 200,000 frozen geese and chickens per week from three Russian depots to New Star Wharf, Lower Shadwell, London over three or four winter months. This trade in frozen food was enabled by the introduction of Linde cold air freezing plants in three Russian depots and the London warehouse. The Shadwell warehouse stored the frozen goods until they were shipped to markets in London, Birmingham, Liverpool and Manchester.
The thermodynamical water activity is thus equal to the relative humidity (RH), and the chemical activity of pure water is equal to one: aw = 1.0. When the atmosphere above a substance, or a solution, is undersaturated in water vapor (p < p*), its water activity is lower than one. Water activity in solutions is directly related to osmotic pressure, although the exact relationship is complex and still the subject of study.
=== Hyperinsulinemic euglycemic clamp === The gold standard for investigating and quantifying insulin resistance is the "hyperinsulinemic euglycemic clamp," so-called because it measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia. It is a type of glucose clamp technique. The test is rarely performed in clinical care, but is used in medical research, for example, to assess the effects of different medications. The rate of glucose infusion commonly is referred to in diabetes literature as the GINF value. The procedure takes about two hours. Through a peripheral vein, insulin is infused at 10–120 mU per m2 per minute. In order to compensate for the insulin infusion, glucose 20% is infused to maintain blood sugar levels between 5 and 5.5 mmol/L. The rate of glucose infusion is determined by checking the blood sugar levels every five to ten minutes. The insulin sensitivity is determined by the rate of glucose infusion during the last thirty minutes of the test. If high levels (7.5 mg/min or higher) are needed, the patient is considered insulin-sensitive. Conversely, very low levels (4.0 mg/min or lower) indicate insulin resistance. Levels falling between 4.0 and 7.5 mg/min are not conclusive and suggest "impaired glucose tolerance," which is an early indication of insulin resistance. This fundamental technique can be greatly enhanced through the utilization of glucose tracers. Glucose can be labeled with either stable or radioactive atoms.
Sources: en.wikipedia.org
Estradiol is an estrane steroid. It is also known as 17β-estradiol (to distinguish it from 17α-estradiol) or as estra-1,3,5(10)-triene-3,17β-diol. It has two hydroxyl groups, one at the C3 position and the other at the 17β position, as well as three double bonds in the A ring. Due to its two hydroxyl groups, estradiol is often abbreviated as E2. The structurally related estrogens, estrone (E1), estriol (E3), and estetrol (E4) have one, three, and four hydroxyl groups, respectively.
In biochemistry, the study of biochemical pathways is an important topic. Such pathways will often display steady-state behavior where the chemical species are unchanging, but there is a continuous dissipation of flux through the pathway. Many, but not all, biochemical pathways evolve to stable, steady states. As a result, the steady state represents an important reference state to study. This is also related to the concept of homeostasis, however, in biochemistry, a steady state can be stable or unstable such as in the case of sustained oscillations or bistable behavior.
=== Photolysis and thermolysis === Photolysis or thermolysis of mononuclear carbonyls generates di- and polymetallic carbonyls such as diiron nonacarbonyl (Fe2(CO)9). On further heating, the products decompose eventually into the metal and carbon monoxide.
sustaining high routine Full Immunized Child (FIC) coverage of at least 90% in all provinces and cities; sustaining the polio-free country for global certification; eliminating measles by 2008; and eliminating neonatal tetanus by 2008.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.